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Introduction.  Patients considered for radical surgery for lung cancer need a functional evaluation to identify those at 
increased risk of postoperative complications. 
Material and methods.  We performed an analysis of clinical data of 1214 patients who underwent a single lobectomy for 
lung cancer. To assess the risk of complications, we used the chronic obstructive pulmonary disease assessment test (CAT). 
Results.  254 pulmonary and 51 cardiovascular complications occurred in 216 (17.8%) patients. In 204 patients with a CAT 
score ≥12 complications occurred more often than in patients with a lower score (26.5% vs. 16.0%; p < 0.001). 
Conclusions.  In patients undergoing lobectomy for lung cancer, pulmonary complications occurred much more frequ-
ently than cardiovascular complications. Patients with a CAT score ≥12 had a higher rate of postoperative complications 
as compared to those with a lower score. 
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Introduction
The goal of preoperative decision making is to minimise 
postoperative complications. Knowing which clinical factors 
are associated with complications permits oncologists, pul-
monologists or surgeons to assess which candidates are ap-
propriate for major thoracic surgery. Patients with lung cancer 
qualified for curative lung resection need an assessment of 
their health status, as they frequently suffer from comorbidities, 
mainly chronic obstructive pulmonary disease (COPD) and 
cardiovascular disease [1, 2], which are considered significant 
prognostic factors [3, 4]. 
The joint European Respiratory Society/European Socie-
ty of Thoracic Surgeons and the American College of Chest 
Physicians [5, 6] recommend a stepwise functional workup of 
lung resection candidates. The assessment begins with a car-
diovascular evaluation using the thoracic revised cardiac risk 
index (ThRCRI), then pulmonary function tests are performed 
with the calculation of predicted postoperative lung function. 
Patients with reduced predictive postoperative lung function 
are referred for exercise tests. 
Current guidelines endorse the thoracic revised cardiac 
risk index (ThRCRI), as a first-line screening tool assessing the 
This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download 
articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
221
cardiac risk before lung resection [7]. The ThRCRI includes 
cardiac ischaemia, cerebrovascular disease, renal disease and 
the extent of resection (pneumonectomy). However, simple 
registration of comorbidities does not provide information 
on the impact of comorbidities on patients’ health. Besides, 
an assessment of the risk of pulmonary complications is not 
included at this stage of the preoperative evaluation. The chro-
nic obstructive pulmonary disease assessment test (CAT) 
was introduced in 2009 as a tool to measure health status 
impairment in patients with COPD [8]. The CAT is a simple, 
patient-completed questionnaire, that covers a broad range 
of effects of COPD on patients’ health. It is a standardised 
assessment tool consisting of only 8 items, that provides re-
liable and valid information on symptoms, activity limitation 
and other manifestations of COPD. We assumed that the CAT 
could also measure the symptomatic effect of other comor-
bidities and be useful in assessing the risk of complications in 
all patients qualified for lung resection, regardless of whether 
they have COPD or not. 
The current study aimed to:
• rate the incidence of pulmonary complications and eva-
luate the need to include these type of complications at 
an early stage of preoperative evaluation; 
• determine the utility of incorporating the CAT in the in-
itial stage of the overall risk assessment of perioperative 
pulmonary and cardiovascular complications in patients 
with lung cancer qualified for lobectomy. 
Materials and methods
The study was accepted by the local ethics committee. 
The participating subjects were patients who had undergo-
ne a single lobectomy for lung cancer at the Department of 
Thoracic Surgery, Institute of Tuberculosis and Lung Diseases 
in Warsaw, between March 2014 and March 2019. Preoperative 
staging included a complete medical history and physical 
examination, blood and urine examinations, a 12-lead resting 
electrocardiogram, pulmonary functional tests (PFT), com-
puted tomography of the chest, and a fibrobronchoscopy. 
In the presence of symptomatic or previously documented 
cardiovascular disease, echocardiography, neck or lower limb 
ultrasound studies were performed. PFT included spirometry 
with measurements of forced expiratory volume in one se-
cond (FEV1) and forced vital capacity (FVC) and a lung transfer 
factor for carbon monoxide (TLco) measurements using the 
single breath method. 
Tests were performed using a MasterScreen system (softwa-
re version 4.65; Jaeger, Würzburg, Germany). We used reference 
values from the 2012 Global Lung Function Initiative for spirome-
try [9] and from the 1993 ERS/European Community for Coal and 
Steel for TLco [10]. The spirometric criterion of COPD diagnosis 
was FEV1/FVC ratio < 0.7 in line with the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) [11]. The classification 
of airflow limitation severity was also taken from the GOLD, 
mild – FEV1 ≥80% predicted, moderate – FEV1 <80% and ≥50% 
predicted, severe – FEV1 <50% and ≥30% predicted. The ThRCRI 
score was calculated according to Brunelli et al. [8]. 
In our study, the ThRCRI included only three classes, as 
patients undergoing pneumonectomy were not included in 
the analysis. The Polish version of the CAT, obtained from the 
website www.catestonline.org, was administered to patients 
while they were waiting for PFT. The patients were briefly in-
formed on how to complete the questionnaire and then filled 
it in independently. The CAT consists of eight items assessing 
cough, phlegm, chest tightness, breathlessness going up a hill/
stairs, activity limitations at home, confidence in leaving home, 
sleep and energy, with 6-point ordinal scales (scored 0–5) of 
severity for each item, that provides a scoring range of 0–40.
Lobectomies were performed by either thoracotomy or 
video-assisted thoracoscopic surgery. Stage I tumours were 
removed using a minimally invasive technique. The surgi-
cal approach was decided by experienced thoracic surge-
ons. Extended lobectomies (e.g. chest wall resections) were 
excluded from the analysis. Complications and deaths were 
those occurring within 30 days postoperatively or later if the 
patient was still in the hospital. The following pulmonary and 
cardiovascular complications were included: prolonged air 
leak, respiratory failure requiring mechanical ventilation for 
more than 48 hours, atelectasis or retention of secretions in 
the airways requiring bronchoscopy, pneumonia, myocardial 
infarction, cardiac failure, pulmonary embolism and death 
of the patient. The degree of severity of complications was 
assigned according to the Clavien-Dindo classification [12]. 
Only life-threatening complications or those requiring surgical 
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Categorical data were tested by the Chi2 test. Tests for com-
plications for CAT score ≥12 vs. CAT score <12 and two more 
such tests included separately COPD and non-COPD patients 
(fig. 1) were adjusted using the Holm-Bonferroni method for 
multiple comparisons with p value thresholds adjusted to be 
respectively: 0.017, 0.025 and 0.05. Lower test p-values were 
met in testing.
Numerical data statistics were presented in the form of 
means with standard deviations (SD). Examining table I, means 
of numerical variables for COPD and non-COPD groups were 
tested using the independent-samples T-Test. P values below 
0.05 for 2-tailed tests were considered statistically significant 
to reject the hypothesis for equality. Analyses were performed 
using scientific computation libraries, SciPy (ver. 1.3) and Num-
py (ver. 1.16.2), in the Python programming language (ver. 3.8).
Results
The demographic and clinical characteristics of the study sub-
jects are shown in table I. Among 1214 subjects, 630 (52%) 
patients met the spirometric criteria of the COPD diagnosis 
(FEV1/FVC < 0.7), of whom 95% were smokers, with mean 
pack-years 35.9 (SD: 21.9). There were 206 (33%) cases with 
mild, 384 (61%) moderate and 40 (6%) with severe airway 
limitation. COPD was the most common comorbidity, follo-
wed by ischaemic heart disease. Cerebrovascular disease and 
renal insufficiency were rare, found in less than 3% of patients. 
The incidence of ischaemic heart disease, cerebrovascular 
disease and renal insufficiency was similar in COPD patients 
and non-COPD patients. The mean CAT score was 6.4 (SD: 5.7, 
range 0–32) and was higher in patients with COPD 6.8 (SD: 
5.9) than in non-COPD patients 5.9 (SD: 5.5; p = 0.005). Surgical 
interventions comprised 434 (36%) right upper, 288 (24%) left 
upper, 210 (17%) left lower, 193 (16%) right lower, and 89 (7%) 
middle lobe lobectomies. 
From the entire group of 1214 patients, 235 pulmonary and 
51 cardiovascular complications were registered, which occur-
red in 216 (17.8%) patients. Grade 3a complications (surgical 
or endoscopic intervention not under general anaesthesia) 
occurred in 168 (13.8%), grade 3b complications (surgical 
or endoscopic intervention under general anaesthesia) in 4 
(0.3%), grade 4a (life-threatening single organ dysfunction) in 
23 (1.9%), grade 4b (life-threatening multi organ dysfunction) in 
12 (1.0%), and grade 5 (the death of the patient) complications 
in 9 (0.7%) patients. 
Based on the analysis of the discrimination of CAT scores 
in relation to complications, patients were divided into two 
groups, CAT score <12 and ≥12. At this CAT bound, the va-
riable was more precise in terms of assessing complications, 
Table I.  Demographic and clinical characteristics of the study patients (n = 1214)
All patients COPD patients




age in years, mean (SD) 65.2 (8.6) 66.4 (7.6) 63.9 (9.3) <0.0001*
male, n (%) 647 (53) 388 (61.6) 259 (44.3) <0.0001**
FEV1, % predicted (SD) 84.0 (19.1) 73.3 (15.7) 95.4 (15.5) <0.0001*
FVC, % predicted (SD) 96.0 (15.4) 94.1 (15.5) 98.1 (15.1) <0.0001*
FEV1/FVC, mean (SD) 0.67 (0.10) 0.60 (0.07) 0.76 (0.04) <0.001*
TLco % predicted (SD) 72.8 (17.6) 68.0 (16.7) 78.0 (17.1) <0.0001*
CAT, mean (SD) 6.4 (5.7) 6.8 (6.0) 5.9 (5.5) 0.006*
ThRCRI^, mean (SD) 0.32 (0.66) 0.35 (0.68) 0.28 (0.63) 0.08*
comorbidity
COPD, n (%) 630 (51.9)
IHD, n (%) 223 (18) 123  (20%) 100 (17) 0.28**
CVD, n (%) 29 (2.4) 19  (3) 10 (2) 0.21**
renal insufficiency, n (%) 5 (0.4) 3  (0.5) 2 (0.4) 0.72**
Tests for COPD vs. non-COPD patients – * T-Test for means; ** Chi2 test; FEV1 – forced expiratory volume in the first second; FVC – forced vital capacity; TLco – lung transfer factor for 
carbon monoxide; IHD – ischemic heart disease; CVD – cerebrovascular disease; SD – standard deviation; ^ – ThRCRI included only three items, without pneumonectomy (score 
range 0–4.5).
Table II. The distribution of patients in each class of the ThRCRI and the CAT
Number of cases
n (%)
Number of cases with 
pulmonary and cardiovascular 
complications n (%)
ThRCRI*
0 972 (80) 164 (16.9)
1–1.5 224 (18.5) 50 (22.2)
2–2.5 5 (0.5) 0
>2.5 12 (1) 2 (16)
CAT
<12 1010 (83) 162 (16.0)
≥12 204 (17) 54 (26.5)
* – ThRCRI included only three items, without pneumonectomy (score range 0–4.5). 
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and score, which  enables rapid and reliable assessment of 
a patient’s health status that can be readily incorporated into 
routine care [16, 17]. The CAT was extensively evaluated in 
COPD patients with varying severity of the disease across 
Europe [18]. In our opinion, symptoms assessed by CAT are 
not limited to COPD and many of them, e.g. breathlessness 
going up a hill/stairs, activity limitation at home, confidence 
in leaving home, sleep and energy levels, are common to lung 
and cardiovascular diseases. That was the reason we decided 
to use the CAT as a tool to assess the risk of pulmonary and 
cardiovascular complications in all patients qualified for lung 
resection. We found that patients with a CAT score ≥12 had 
more complications than patients with a lower CAT score and 
the higher incidence of complications was independent of 
the COPD diagnosis. The CAT identified the high-risk group at 
a very early stage of functional workup before PFT or exercise 
tests were performed. It is difficult to compare the results of 
our study with other series because we have found only one 
study aimed at verifying the usefulness of symptoms or quality 
of life-based scores, including the CAT, in predicting the risk 
of pulmonary postoperative complications in patients with 
early-stage COPD [19]. 
Our study is the first in which the CAT was used in a large 
group of patients qualified for thoracic surgery regardless 
of COPD diagnosis. It is worth mentioning that the analysis 
in the current study differs from those by Brunelli et al. [7] 
and Ferguson et al. [13]. The series by Brunelli and Ferguson 
included patients who underwent lung resection for benign 
and malignant diagnoses, and our study group included only 
patients with lung cancer undergoing a single lobectomy 
– the most common type of resection (89% of resection 
surgeries for lung cancer in our hospital). In this way, we got 
a large and homogeneous group of patients in terms of the 
extent of surgery, something we consider a strength of our 
study. Patients undergoing elective pneumonectomy were 
excluded from the analysis because we think these patients 
should undergo a separate functional workup, since such an 
extensive procedure is a very strong risk factor – indepen-
dent of the accompanying diseases and the patient’s state 
of health. In practice, in patients undergoing lobectomy, only 
ischaemic heart disease was a prevalent ThRCRI criterion, 
since renal insufficiency and cerebrovascular disease were 
rare, and found in less than 3% of patients. Moreover, our 
analysis embraced not only cardiovascular, but also pulmo-
nary perioperative complications, which were much more 
common. In  this context, the CAT, which turned out to be 
more effective, could replace the THRCRI in the pre-operative 
functional assessment algorithm.
In conclusion, pulmonary complications, occurring much 
more frequently than cardiovascular complications, should 
be included in the risk assessment scheme for lung resection. 
The CAT turned out to be an effective and easy to apply in practi-
ce instrument for initial risk assessment in patients with lung can-
compared to other tested thresholds, and at the same time 
included a fairly large number of patients with complications. 
The distribution of patients in classes of the ThRCRI and the 
CAT, and the number of cardiovascular and pulmonary com-
plications in each class are shown in table II.
In the analysed group, the maximum value of the ThRCRI 
could be 4.5, not 5.5, because pneumonectomy was an exc-
lusion criterion. 20% of patients had ThRCRI greater than zero, 
mainly due to comorbid ischaemic heart disease. The rate of 
pulmonary and cardiovascular complications increased in 
patients with a ThRCRI score ≥1, 21.5% vs. 16.9% (Chi2 test; 
p = 0.048). The incidence of complications by CAT score in 
the whole group, in COPD and non-COPD patients, is shown 
in figure 1.
There were 204 (16.8% of the whole group) patients with 
a CAT score ≥12, and in these patients, complications occur-
red more often than in patients with a lower score (26.5% vs. 
16.0%, Chi2 test; p < 0.001). This difference was true both in 
COPD patients (30,9% vs. 21,9%, p < 0.04) and in non-COPD 
patients (19.7% vs. 10.1%, p < 0.02). In COPD patients, the rate of 
complications increased with the severity of airway limitation, 
16%, 27% and 30% in patients with mild, moderate and severe 
airway obstruction respectively.
Conclusions
Thoracic surgery is considered high-risk surgery but remains 
the best therapeutic option for a cure in patients with resec-
table non-small cell lung cancer. Patients with lung cancer 
who are considered for radical surgery should be assessed 
to identify subjects at increased risk of perioperative compli-
cations. The initial step in the current algorithm of functional 
qualification focused on cardiovascular complications has 
limitations. The incidence of major cardiac complications is 
low – 3.3% in the series by Brunelli et al. [8], 4.1% in the series 
by Ferguson et al. [13] and in our group. 
We found major pulmonary complications more than four 
times more common than cardiovascular complications, so the 
risk of this type of complication should be assessed from the 
beginning of the functional workup. Pulmonary function tests, 
which are the second step of the functional workup, allow for 
the calculation of predictive postoperative lung function, but 
they are not a good tool for health status assessment. Several 
studies have indicated that the relationship between lung 
function and health status scores is weak [14, 15]. We used the 
CAT, a simple instrument to assess the symptomatic impact 
on patients’ health. The CAT was developed as an instrument 
to measure the health status of patients with COPD in an easy 
way [9]. The CAT covers all the important symptomatic areas of 
COPD and consists of only 8 items that provides a quantified 
measure of health status. 
The item selection process followed a vigorous metho-
dology and created a questionnaire with very good measu-
rement properties. It requires only 2–3 minutes to complete 
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cer qualified for lobectomy. Patients with a CAT score ≥12 had 
a higher rate of pulmonary and cardiovascular complications 
as compared to those with a lower score. The CAT has enabled 
simple early identification of patients in the high-risk group 
who require the most thorough further functional assessment. 
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